Press Release FeedGet the RSS feed
Menu

Business Wire

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Business Wire

PASADENA, Calif., October 19, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma (ccRCC).

The live webcast of the conference call may be accessed through this link and through "Events & Presentations" in the Investors section of the Company's website, located at investors.xencor.com. A recording will be available for at least 30 days.

ESMO Presentation to Highlight Results for Intravenous Doses Evaluated for Recommended Phase 3 Dose Selection in ccRCC

Results from the Phase 1 study of XmAb819 in advanced clear cell renal cell carcinoma (ccRCC) will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 being held in Madrid, Spain. Details of the presentation:

  • Title: Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)

  • Session: Proffered paper 2: Genitourinary tumours, renal and urothelial

  • Session Date/Time: Sunday, October 25, 2026, 8:30 a.m. – 10:00 a.m. CET

  • Session Location: IFEMA Madrid, Almeria Auditorium – Hall 9

  • Presenter: Sumanta Pal, M.D., FASCO, Professor and Vice Chair of Academic Affairs, City of Hope Comprehensive Cancer Center

XmAb819 Evaluation Across Advanced ccRCC and ENPP3+ Tumors

XmAb819 is being evaluated for the treatment of patients with advanced ccRCC and ENPP3+ tumors in a Phase 1 clinical study (Clinicaltrials.gov Identifier: NCT05433142). Xencor is planning to initiate a registration-enabling study of XmAb819 monotherapy in advanced ccRCC in 2027. Currently:

  • Expansion cohorts are evaluating intravenous doses to support selection of a dose for the planned Phase 3 pivotal study for patients with advanced ccRCC,

  • Dose escalation of subcutaneous administration in advanced ccRCC is ongoing,

  • A sub-study for patients with ENPP3+ advanced colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma opened to enrollment in the second quarter of 2026, and

  • A sub-study for patients with intermediate- or poor-risk advanced ccRCC who have progressed after nivolumab in combination with ipilimumab as a first-line treatment (IO doublet therapy) opened to enrollment in the third quarter of 2026.

  1. CybersecurityZumigo, Inc.Zumigo InstaAuth Achieves FIDO2 Server Certification, Bringing Frictionless, Secure Passkey Sign-In to Banks, Fintechs, and MerchantsFull certification from the FIDO Alliance validates InstaAuth's phishing-resistant passkey authentication across real-world devices, available now in the Auth Widget and IDV Builder SAN JOSE, Calif., October 19, 2026--Zumigo, Inc., a leader in mobile identity intelligence and fraud prevention, today an
  2. FinanceNRG Energy, Inc.NRG Energy, Inc. Announces Quarterly DividendCompanies: NRG EnergyHOUSTON, October 19, 2026--NRG Energy, Inc. (NYSE: NRG) today announced that its Board of Directors declared a quarterly dividend on the Company's common stock of $0.475 per share, or $1.90 per share on an annualized basis. The dividend is payable on November 16, 2026, to stockholders of record as of N
  3. HealthcareFrontier Medicines to Present First Clinical Data for FMC-376, an Equipotent KRAS G12C ON+OFF Inhibitor, at ESMO Congress 2026BOSTON & SOUTH SAN FRANCISCO, Calif., October 19, 2026--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the company will pr
  4. FinanceTaiho Oncology, Inc. and Cullinan Therapeutics, Inc.Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS MetastasesIntracranial Objective Response Rate of 30.2% was observed in 43 evaluable patients Results to be shared in poster presentation at ESMO Congress 2026 PRINCETON, N.J. & CAMBRIDGE, Mass., October 19, 2026--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Co
  5. HealthcareUnited Therapeutics CorporationUnited Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPDThe development of a soft mist inhaler ( SMI ) represents a further advancement of treprostinil delivery devices to potentially address a wider range of patient tolerability profiles A soft mist formulation may be beneficial for patients with pulmonary hypertension associated with chronic obstructive pulmonary disease ( P
  6. FinanceBlackSky Technology Inc.BlackSky to Host Third Quarter 2026 Results Conference CallHERNDON, Va., October 19, 2026--BlackSky Technology Inc. (NYSE: BKSY ) will host a live webcast and conference call to discuss third quarter 2026 financial results and its business outlook on Thursday, November 5, 2026, at 8:30 a.m. EST. A press release with BlackSky's financial results will be release